BTCS Inc (OTCMKTS:BTCS) Gets Market Disapproval for Merger Plans

BTCS Inc (OTCMKTS:BTCS)

Shares of BTCS Inc (OTCMKTS:BTCS) tumbled 8.13% after the company announced plans to merge with Australian blockchain company, Blockchain Global Limited. The two companies have signed a non-binding Letter of Intent that paves way for the protracted merger, subject to a number of conditions.

Investors Reaction

The merger push appears to have rattled investors as BTCS Inc (OTCMKTS:BTCS) tumbled from this year’s highs of $0.42 a share to current to $0.23 a share. The stock faces immediate support at the $0.21 level below which it could tumble to lows of $0.11, depending on the strength of the sell-off wave. Monday’s sell-off is threatening to reverse a bull run that begun last month helping push the stock from lows of $0.05 a share.

BTCS Inc (OTCMKTS:BTCS) is a blockchain company that operates a beta e-commerce marketplace that accepts digital currencies. The site offers secure ways of storing Bitcoin currencies in addition to marketing 250,000 products. In a bid to pursue growth around blockchain technology, the company has developed a secure digital currency solution dubbed BTCS wallet.

BTCS-Blockchain Global Limited Merger

Blockchain Global Limited which BTCS Inc. (OTCMKTS:BTCS) plans to merge after generating revenues of $4.4 million last year, representing a 300% year over year increase. The company has approximately $3.5 million in assets made up of cash and Bitcoin. It operates under four distinct business lines as an institutional exchange platform, transaction verification services, a blockchain startup accelerator, and a blockchain technology consultancy.

“In addition to our work with innovative companies through the Melbourne Blockchain Center, we’ve also positioned ourselves to be a leading consultant in the space, servicing companies that recognize the importance of incorporating blockchain technology into their organizational strategies,” said Sam Lee BCG CEO.

Merger Terms

The Letter of intent signed is subject to the approval of BCG’S shareholders in addition to BTCS Inc. (OTCMKTS:BTCS)’s board of directors approving the transaction. Under the terms of the agreement, BCG shareholders are to receive a combination of common stock as well as convertible preferred stock and warrants equaling 75% of the combined company.

The Letter of Intent, if approved, will also result in current executive officers receiving 12% of the fully diluted equity in the form of common stock. Insiders of the combined company will also have to agree to a one year lock up on any equity issued in connection with the merger transaction.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BTCS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Viaderma Inc (OTCMKTS:VDRM) Anticipating Japan Sales

Viaderma Inc (OTCMKTS:VDRM)

Shares of Viaderma Inc (OTCMKTS:VDRM) were up by 30.77’% days after the specialty pharmaceutical company announced the appointment of a sales group for its topical antibiotic. Galaxy Solutions Inc. is to sell the product under the brand name Vitastem, first targeting customers in select markets of Asia Pacific.

Viaderma Inc (OTCMKTS:VDRM)
One month stock price chart for VDRM

Monday’s rally helped push the stock close to a key resistance level of $0.03 a share. The stock is currently trading at the higher end of a tight $0.02-$0.03 a share having been on an impressive run since the start of the month.  A rally above the $0.03 could push the stock to highs of $0.05 mark which is another key resistance level.

Viaderma Inc. (OTCMKTS:VDRM) is a specialty pharmaceutical company focused on bringing to market new products through research and development. The company licenses and sells products developed using stem-cell therapy for the treatment of various infectious diseases. TetraStem is the company’s candidate product in development for the treatment of genital herpes. It is also working on antifungal products for onychomycosis.

Galaxy Solutions Agreement

Under the terms of the agreement, Galaxy Solutions will assume sales and marketing responsibilities for the Vitastem brands in addition to other brands that will be developed for other market segments. Galaxy Solutions will also sell directly to other large customers and distributors in addition to acting as the primary provider of service and support in markets of focus.

“With Galaxy Solutions as our sales representative, we will immediately have access to the professional segment of our target markets. Our goal is to continuously increase our revenues and improve our customers’ experience in every aspect,” said Mr. Otiko.

Sales Expectations

Viaderma Inc (OTCMKTS:VDRM) has already begun product testing of the topical antibiotic in anticipation of the first orders in the next 30-45 days. The company expects sales of about 10,000 units over the next 4-6 months which should double to 20,000 units early next year.

Viaderma Inc (OTCMKTS:VDRM) Chief Executive officer, Chris Otiko, expects Galaxy Solutions to help expand the company sales network in addition to providing personnel support. The executive also expects the partnership to allow the company introduce other products to several markets across Japan as well as the larger Asia Pacific.

Buoyed by the agreement with Galaxy Solutions, the Chief executive officer is estimating revenues of about $12 million with the sale of Vitastem in Japan.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $VDRM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Easton Pharmaceuticals Inc (OTCMKTS:EAPH) Invests in Marijuana Cultivation

Easton Pharmaceuticals Inc (OTCMKTS:EAPH)

Easton Pharmaceuticals Inc (OTCMKTS:EAPH) traded higher days after announcing the closing of an agreement with Alliance Group for the cultivation, production, and sale of medical/recreational cannabis. The stock was up by 6.62% in Monday’s trading session to end the day at $0.029 a share. It now awaits to be seen if the current momentum is strong enough to reverse a strong downward trend that started early in the year on the stock rallying to highs of $0.05 a share.

Easton Pharmaceuticals Inc (OTCMKTS:EAPH)
One month stock price chart for EAPH

Easton Pharmaceuticals Inc (OTCMKTS:EAPH) is a development stage company focused on various pharmaceutical sectors and industries. The company develops and markets various drugs and healthcare products for the treatment of cancer and other health problems. The company has also recently started to pursue growth opportunities in the multibillion legal cannabis business.

Alliance Group Investment

Easton Pharmaceuticals Inc (OTCMKTS:EAPH) has made a $575,000 payment to Alliance Group that allows it to gain interest to 45 acres of a 135-acre parcel of a zoned land north of Toronto Ontario Canada. The payment is to facilitate the cultivation production and sales of medical marijuana. In addition, the payment is to be used to pursue other lucrative revenue-producing businesses

Alliance Group is currently seeking the necessary permits required to grow legal medical and recreational marijuana. Under the terms of the agreement, Easton Pharmaceuticals Inc (OTCMKTS:EAPH) is entitled to 50% of all revenues that will be generated from the business which is expected to begin in the next 30 days. Easton Pharmaceuticals Inc (OTCMKTS:EAPH) and Alliance Group expect the business to generate millions of dollars in revenues in its first year.

“We are very pleased to have entered and closed with Easton Pharmaceuticals as we believe Easton’s investment and partnership will be very lucrative to both parties. Additional positive updates are forthcoming,” Alliance Group CEO in a statement.

Separately, Easton Pharmaceuticals Inc (OTCMKTS:EAPH) has closed a sub-distribution agreement with Gedeon Richter Plc. for the product AmnioSense. The agreement represents the second product launch with the distributor following the launch of Gynofit in the second quarter. The patented amniotic fluid leak test, AmnioSense, is to be marketed in two presentations as the two companies look to capture maximum market share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EAPH and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

HempAmericana Inc (OTCMKTS:HMPQ) Eyes Institutional Investors

HempAmericana Inc (OTCMKTS:HMPQ)

HempAmericana Inc (OTCMKTS:HMPQ) rallied 11.18% as investors reacted to a number of strategic partnerships the company has recently inked. Selection of the company as the featured investment on a crowd funding site, minivest.com, also continues to fuel bullish momentum.

HempAmericana Inc (OTCMKTS:HMPQ)
One month stock price chart for HMPQ

Monday’s rally helped uphold a rally that shares of HempAmericana Inc (OTCMKTS:HMPQ) began early this month. The stock is currently trading at the higher end of $0.01-$0.02 trading range ahead of immediate resistance at $0.03.

HempAmericana Inc (OTCMKTS:HMPQ) is a development stage company with stakes in the multibillion industrial hemp market. The company researches and develops industrial hemp in addition to providing hemp bags, hemp clothing, and hemp rolling paper products.

HempAmericana’s Strategic Partnership

The researcher and developer of industrial hemp products is currently finalizing negotiations for two strategic partnerships in Maine and New York. The partnership in Maine is for the development of a unique C02 low temperature, fluid oxygen, extraction machine. The company is on course to receive hundreds of thousands of dollars for the one of a kind extraction machine.

The strategic partnership in New York is for the growing of industrial hemp on 650 acres of land. The property in question also includes a 50,000 square foot facility where HempAmericana plans to operate an onsite extraction lab.

“We’re lowering our cost and increasing margins by shifting production from international to domestic. We plan on capturing a significant market share of the extraction business by scaling our extraction lab model to all 50 states and making them accessible to domestic and international companies,” said CEO, Salvador Rosillo.

The signing of strategic partnerships in Maine and New York comes at a time when HempAmericana is aggressively pursuing investment partners. The listing of the company in minvest.com strategically positions the company to receive investments of up to $500,000 from both institutional and retail investors.

Growing HMPQ Shareholder Base

Listing on Minivest.com according to the chief executive officer marks yet another milestone which could see the company attracting a diverse group of investors. The executive also expects the listing to help strengthen the company’s current shareholder base.

In addition to pursuing strategic partnerships and investments, the company HempAmericana Inc (OTCMKTS:HMPQ) has also started to sell its own CBD oil off its newly designed website. The company has also purchased an extraction machine that it plans to use to further strengthen its product line.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $HMPQ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Bad News for CARDIOME PHARMA CORP (NASDAQ:CRME)

CARDIOME PHARMA CORP(NASDAQ:CRME)

CARDIOME PHARMA CORP (NASDAQ:CRME) stock dropped around 33% after the company revealed that the U.S. Food and Drug Administration (FDA) advised Cardiome that the proposed data package would not be sufficient to support a resubmission of the BRINAVESS® New Drug Application (NDA). CRME shares trade over ten times their 30-day, daily volume figure. Cardiome Pharma Corp. is a pharmaceutical company, that develops and commercializes treatments for patients that are afflicted with heart disease.

CARDIOME PHARMA CORP (NASDAQ:CRME) is a pharmaceutical company that develops and commercializes innovative therapies that will improve the quality of life and health of patients suffering from disease. Cardiome has two cardiology products, BRINAVESS® (vernakalant IV), approved in Europe, Canada, and other countries for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl) a reversible GP IIB/IIIa inhibitor indicated for use in patients with acute coronary syndrome. Cardiome also commercializes other products that are approved in countries around the world.

Shares of CARDIOME PHARMA CORP (NASDAQ:CRME) hit their 2017 high in July. However, since then the stock has lost ground every week. For the past ten trading days, CRME stock traded just south of $4.00 as it continuously attempted to break through resistance. However the news that hit today sent the stock gapping down and it opened at $#3.36 before closing at $2.60 for a daily loss of $$1.27 or 33%.

Adjusted for dilution, shares of CARDIOME PHARMA CORP (NASDAQ:CRME) had traded above $35 for most of 2010 before falling fast and trading under $2.00 for most of 2012 and 2013. Towards the end of 2013 and through 2014 CRME stock traded above $5.00 then fell back again. Today’s decline represents the largest single day loss in the past year. CRME’s Relative Strength Index (RSI) is under 10. Most market professionals believe that a RSI value under 20 represents an “oversold” condition.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CRME and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Market Ignores ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) Patent Award

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) rose on news that the biopharmaceutical firm was issued a patent, US 9,714,271, covering a broad collection of cyclophilin inhibitors. The newly granted patent significantly extends the claims of the original CRV431 patent family. News about the patent caused CTRV shares to open on their inter-day high, $0.65, before sellers stepped in a sent the stock back down $0.01 below Friday’s close of $0.60.

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)
One month stock price chart for CTRV

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) is a biopharmaceutical company that develops antiviral drugs with an emphasis on the treatment of Hepatitis B virus (HBV) infections. ContraVir currently has a lead cyclophilin inhibitor, CRV431 (US Patent 9,200,038), for use as an antiviral which ContraVir is developing as a treatment for the hepatitis B virus (HBV). The Company believes that CRV431 will be used in conjunction with tenofovir exalidex (TXLTM), its lead drug currently in Phase 2 clinical trials.

James Sapirstein, Chief Executive Officer of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) stated in the press release, “We are very pleased to have received the issuance of this additional patent, as it provides broad coverage of many compounds within our library of cyclophilin inhibitors. This also positions us for opportunities to potentially treat other diseases. Having a patented portfolio of cyclophilin inhibitors allows us to access additional disease indications and potentially expand beyond our core program in HBV.”

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) has posted losses every year since 2012 when it reported a loss of (-).02) per share followed by annual per share losses of (-$0.41), (-$1.02), and, for 2016 a loss of (-$0.63) per share. Meanwhile the company has diluted shareholders each year. In 2013, there were 9 million shares outstanding and by 2016 that number grew to 27.06 million. The analyst’s consensus target price for CTRV shares if $6.00.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CTRV and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.